readthroughSign in
Oct 14, 2026Weekly roundupUpdated

Takeda gets two mesalamine label approvals; psoriatic arthritis trial still not recruiting

FDA approved labeling supplements for Pentasa and Lialda, while Takeda's new zasocitinib Phase 3b trial in psoriatic arthritis remains unchanged from last week.

Takeda's week included two FDA approvals alongside its previously disclosed psoriatic arthritis study.

  • The FDA approved a labeling supplement for Takeda's Pentasa (mesalamine extended-release capsules, 250MG and 500MG), under NDA020049 supplement 44, with the submission marked approved as of status date 2026-10-141.
  • The FDA also approved a labeling supplement for Takeda's Lialda (mesalamine delayed-release tablets, 1.2GM), under NDA022000 supplement 30, also approved as of status date 2026-10-142.
  • "LATITUDE PsA NeXt" (NCT07871721) is a Phase 3b trial of zasocitinib (TAK-279), assessing how well the drug works and how safe it is in participants with active psoriatic arthritis who have not previously received biological medicines3. The study remains not yet recruiting, with an estimated enrollment of 644 participants3.

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.